血必净治疗产科高凝状态的临床研究  

Clinical research of Xuebijing in the treatment of obstetric hypercoagulable state

作　　者：罗志丽[1] 谭峰[1] 吴玉华[1] 杨小海[1] 李志英[1] 陈尚萍[1] 

机构地区：[1]广东省茂名市人民医院产科,广东茂名525000

出　　处：《中国医药科学》2014年第8期58-59,68,共3页China Medicine And Pharmacy

摘　　要：目的：探讨血必净在产科高凝状态中的临床预防治疗效果。方法选择2011年6月~2013年6月住院的72例重度子痫前期患者作为研究对象，系统随机化法将其分为两组，对照组（36例）术后静脉滴注葛根素治疗，观察组（36例）术后静脉滴注血必净治疗，比较两组生产前后的凝血指标。结果观察组产后纤维蛋白原和血细胞积压两个指标值均明显下降（P＜0.05），D-二聚体指标平均值上升，但差异无统计学意义（P＞0.05）；对照组产前、产后血细胞积压、纤维蛋白原及D-二聚体3项标准均未见明显差异（P＞0.05）。结论血必净在预防治疗重度子痫前期高凝状态的临床效果显著，值得临床借鉴推广。Objective To investigate clinical preventive effect of Xuebijing in the treatment of obstetric hypercoagulable state. Methods 72 cases of patients with severe preeclampsia were selected as research object, who accessed in our hospital from June 2011 to June 2013.The patients were divided into 2 groups, according to system randomization method. Puerarin was taken by the control group（36 cases） with intravenous infusion. Xuebijing was taken by the observation group（36 cases） with intravenous infusion. Coagulation parameters of both groups were then observed and compared. Results Postnatal fibrinogen and blood cells backlog of observation group significantly decreased（P 0.05）. Conclusion Xuebijing has a significant clinical preventive effect in the treatment of severe preeclampsia hypercoagulable state, which is worthy of clinical promotion.

关 键 词：重度子痫前期 高凝状态 血必净 产科 凝血功能障碍 

分 类 号：R714[医药卫生—妇产科学]